Cannabics® MLN-33
Melanoma
DiscoveryOutline for POC study in mice
Key Facts
About CNBX Pharmaceuticals
CNBX Pharmaceuticals is a clinical-stage biotech focused on discovering and developing cannabinoid-derived medicines for cancer and neuropsychiatric conditions. Its core strategy utilizes a proprietary drug discovery platform combining high-throughput screening and bioinformatics to identify potent cannabinoid formulations. The company's lead candidate, RCC-33 for colorectal cancer, is in late preclinical development, with a broader pipeline targeting melanoma, breast cancer, and neuropsychiatry. CNBX operates as a public entity, with its core R&D conducted through its Israeli subsidiary, Cannabics Pharmaceuticals.
View full company profileTherapeutic Areas
Other Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ABD-3001 | Advanced Biodesign | Phase 1 |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| AV-MEL-1 | AIVITA Biomedical | Phase 1B |
| Melanoma Immunotherapy | Vaccizone | Pre-clinical |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Melanoma Monitoring Solution | Oncobit | Commercial |
| Undisclosed Enhanced Antibody Program | Score Pharma | Pre-clinical |
| ASO for Melanoma | Carnation Therapeutics | Pre-clinical |
| Personalized DNA Cancer Vaccine | Neomatrix | Pre-clinical |